Psychiatric Effects
- Some patients newly initiating a GLP-1 receptor agonist may experience rapid onset of psychiatric symptoms, as evidenced by a few case reports.
Case Studies
- Case 1:
- A 42-year-old female with a medical history including bipolar I disorder, PTSD, morbid obesity, and type 2 diabetes.
- Considered ineligible for bariatric surgery due to her psychiatric background, she commenced treatment with semaglutide (Ozempic).
- Within just 3 weeks of initiating semaglutide, the patient exhibited behavioral disturbances, prolonged nihilistic delusions, and attempted self-strangulation.
- Reported by Shahan Syed, MD, of Bergen New Bridge Medical Center in Paramus, New Jersey, at the American Psychiatric Association (APA) annual meeting.
- Subsequent cessation of semaglutide resulted in a gradual reversal of suicidal ideation and behavior.
Expert Insights
- Dr. Shahan Syed emphasizes the potential increase in such cases due to the widespread prescription of GLP-1 receptor agonists.
- Even patients without prior psychiatric history should undergo weekly evaluations to monitor mood, sleep, appetite, and anxiety levels.
Exploring Medication Mechanisms
- GLP-1 receptor agonists, like semaglutide, are gaining popularity for their beneficial effects on fat cells and muscles.
- However, their impact on the brain remains uncertain, raising questions about potential psychiatric side effects.
Vigilance in Prescribing
Understanding the risk of psychiatric symptoms associated with GLP-1 receptor agonists is crucial for healthcare providers. Regular monitoring and prompt intervention can mitigate adverse effects and ensure patient safety.